Is CStone Pharmaceuticals (SEHK:2616) Fully Valued On Interim Results And CS2009 Progress?

CStone Pharmaceuticals (SEHK:2616) stock is in focus after the company released its 2026 interim update, highlighting fresh CS2009 clinical data, stronger pralsetinib uptake, and progress toward global Phase III trials.

At a latest share price of HK$6.18, CStone Pharmaceuticals has seen a 1 month share price return of 42.07% and a 90 day share price return of 23.35%. However, the 1 year total shareholder return declined 48.93%, which hints that recent clinical and interim results have improved sentiment but follow a period where investors previously reassessed risk and growth expectations.

Compare CStone Pharmaceuticals with other oncology focused growth stories by scanning our hand picked 616 high quality undiscovered gems for companies that pair clinical progress with strengthening fundamentals.

CStone Pharmaceuticals now has fast improving clinical momentum and a sharp share price rebound. The bigger question for you is whether the stock already reflects this progress or still trades at a discount.

Preferred Price to Sales Multiple of 19.9x: Is It Justified for CStone Pharmaceuticals?

The latest Simply Wall St checks suggest CStone Pharmaceuticals, at a last close of HK$6.18, carries a P/S multiple of 19.9x, which screens as expensive against both its own fair ratio and peers.

The P/S multiple compares the company’s market value to its revenue. For a biopharmaceutical stock like CStone Pharmaceuticals that is currently loss making, investors often look at P/S because earnings are not yet a reliable guide.

Here, the current P/S of 19.9x is above the estimated fair P/S ratio of 6.3x. It is also higher than the peer average P/S of 18.1x and the Hong Kong Biotechs industry average of 9.7x. That suggests the market is paying a premium for CStone Pharmaceuticals compared to similar companies and to the level that the SWS fair ratio indicates the multiple could move toward over time, even though the company is still unprofitable.

The current P/S multiple and the estimated fair ratio can be put in context by examining the SWS fair ratio workup for CStone Pharmaceuticals. Explore the SWS fair ratio for CStone Pharmaceuticals

Result: Price-to-Sales of 19.9x (OVERVALUED)

However, CStone Pharmaceuticals still carries execution risk around late stage trials and remains loss making, which could quickly challenge the recent sentiment shift.

Find out about the key risks to this CStone Pharmaceuticals narrative.

Another View on CStone Pharmaceuticals Using the SWS DCF Model

The P/S workup flags CStone Pharmaceuticals as expensive at 19.9x, yet the SWS DCF model points the other way. At a share price of HK$6.18, the stock is trading about 55.8% below an intrinsic value estimate of HK$13.97. Which signal do you trust more?

To see how the cash flow based view is built and what assumptions sit behind it, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CStone Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 265 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around CStone Pharmaceuticals have you weighing the upside against the risks, take a moment to review the evidence directly and then move quickly if you want to shape your own view. To see what investors are optimistic about and how those potential rewards compare, check the 2 key rewards

Looking for more investment ideas beyond CStone Pharmaceuticals?

If you rate CStone Pharmaceuticals worth tracking, you probably do not want to miss other stocks that match clear, data driven qualities using the Simply Wall St Screener.

• Spot potential turnaround stories early by scanning 213 elite penny stocks with strong financials that already show stronger balance sheets and improving business quality.
• Target quality at a measured price by reviewing the 265 high quality undervalued stocks that combine healthier cash flows with more robust fundamentals.
• Reduce portfolio stress and focus on resilience by checking the 269 resilient stocks with low risk scores identified using Simply Wall St's risk scoring.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com